Publications by authors named "Mahtab Marker"

Claim this Profile
A
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.
Phillip M Rappold, Lynda Vuong, Josef Leibold, Nicholas H Chakiryan, Michael Curry, Mahtab Marker

Cancer Discov· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
Mahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, Georgina V Long, Keith T Flaherty, Mahtab Marker

Lancet Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.
A Ari Hakimi, Martin H Voss, Fengshen Kuo, Alejandro Sanchez, Ming Liu, Mahtab Marker

Cancer Discov· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTEN Expression, Not Mutation Status in , or , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.
Martin H Voss, David Chen, Albert Reising, Mahtab Marker, Jiayuan Shi

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Martin H Voss, Albert Reising, Yuan Cheng, Parul Patel, Mahtab Marker

Lancet Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14.
James J Hsieh, Mahtab Marker, David Chen

Eur Urol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Alessandro Maria Vannucchi, Srdan Verstovsek, Paola Guglielmelli, Martin Griesshammer, Timothy C Burn, Mahtab Marker

Ann Hematol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
James J Hsieh, David Chen, Patricia I Wang, Mahtab Marker, Almedina Redzematovic

Eur Urol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.
Martin H Voss, David Chen, Mahtab Marker, A Ari Hakimi, Chung-Han Lee

Br J Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Robert J Motzer, Camillo Porta, Nicholas J Vogelzang, Cora N Sternberg, Cezary Szczylik, Mahtab Marker

Lancet Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis